1110 related articles for article (PubMed ID: 34245682)
1. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
2. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
[TBL] [Abstract][Full Text] [Related]
3. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Gingras G; Jit M; Boily MC; Bloem P; Brisson M
Lancet Public Health; 2023 Oct; 8(10):e788-e799. PubMed ID: 37777288
[TBL] [Abstract][Full Text] [Related]
4. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
6. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
8. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
9. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
10. Impact and Cost-Effectiveness of Human Papillomavirus Vaccination Campaigns.
Portnoy A; Campos NG; Sy S; Burger EA; Cohen J; Regan C; Kim JJ
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):22-30. PubMed ID: 31666282
[TBL] [Abstract][Full Text] [Related]
11. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
13. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
14. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
15. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
Sharma M; Sy S; Kim JJ
BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
[TBL] [Abstract][Full Text] [Related]
16. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
17. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
Kiatpongsan S; Kim JJ
PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
[TBL] [Abstract][Full Text] [Related]
18. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
19. The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach.
Chanthavilay P; Reinharz D; Mayxay M; Phongsavan K; Marsden DE; Moore L; White LJ
BMC Health Serv Res; 2016 Aug; 16(1):418. PubMed ID: 27549921
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
